Andrew M. Scott

Ductile iron jacking pipes

Andrew M. Scott, 1994 .

Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

Webster K. Cavenee, Edouard C. Nice, Lloyd J. Old, 2009, Proceedings of the National Academy of Sciences.

Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent

Lester J. Peters, Rodney J. Hicks, Richard Fisher, 2005, European Journal of Nuclear Medicine and Molecular Imaging.

A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake

Robert Jones, Edouard C. Nice, Lloyd J. Old, 2005, Clinical Cancer Research.

Assessment of the role of FDG PET in the diagnosis and management of children with refractory epilepsy

David C. Reutens, Samuel F. Berkovic, Christopher C. Rowe, 2005, European Journal of Nuclear Medicine and Molecular Imaging.

Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector

Andrew M. Scott, Alexander A. Kortt, Barbara E. Power, 2001, Cancer Immunology, Immunotherapy.

Efficiency of T‐cell costimulation by CD80 and CD86 cross‐linking correlates with calcium entry

Stefan Bauer, Andrew M. Scott, A. Scott, 2010, Immunology.

Bridging Bio-Nano Science and Cancer Nanomedicine.

Kristofer J. Thurecht, Frank Caruso, Andrew M. Scott, 2017, ACS nano.

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

Hao Xiong, Helen Wheeler, John Simes, 2017, Cancer Chemotherapy and Pharmacology.

Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma

Lloyd J. Old, Tim Saunder, Andrew M. Scott, 2005, Clinical Cancer Research.